Werewolf Therapeutics, Inc. (HOWL) Tops Q2 EPS by 7c

Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q2 EPS of ($0.40), $0.07 better than the analyst estimate of ($0.47).

For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.

You May Also Be Interested In

• Raymond James Starts Rocket Lab USA (RKLB) at Outperform
• RH (RH) Tops Q2 EPS by $2.31
• iShares 20+ Year Treasury Bond ETF (TLT) call put ratio 1 call to 1.1 puts on 1.5M contracts